Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Temozolomide in First-Line Glioblastoma Multiforme
NCT00544817Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in glioblastoma multiforme (GBM), sponsored by SCRI Development Innovations. Started Apr 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00544817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544817.